Combined PARP and WEE1 inhibitor treatment at clinically relevant doses reduced the growth rates of both tumour models as well as significantly improved survival compared with olaparib monotherapy and the vehicle treated controls (Fig. 2a). This evidence concerns the gene WEE1 and neoplasm.